Dr. Francesca Gay on the FORTE Study

What is the background of this study?

Cytogenetic abnormalities (CA) are one of the most powerful prognostic factors in multiple myeloma. In the FORTE study, carfilzomib-lenalidomide-dexamethasone induction/consolidation with ASCT (KRd_ASCT) significantly improved progression-free survival (PFS) vs KRd without ASCT (KRd12, Hazard Ratio 0.64) or carfilzomib-cyclophosphamide-dexamethasone (KCd) plus ASCT (KCd_ASCT, Hazard Ratio 0.53). KR maintenance significantly improved PFS vs R (HR 0.63).

In this video:

Dr. Francesca Gay (University of Torino, Torino, Italy) explains that, for this study, multiple myeloma patients were randomized to KRd with ASCT vs KCd without ASCT vs KRd12 and, thereafter, to KR vs R maintenance. The study’s objective was to determine the impact of treatment on progression-free survival according to patient risk.

Conclusions:

KRd_ASCT and KR maintenance are highly effective in standard-risk, high-risk, and double-hit patients, with impressive four-year progression-free survival from diagnosis (KRd_ASCT: HiR 62%, DH 55%) and three-year progression-free survival from maintenance (KR: HiR 69%, DH 67%). These results support the use of these combinations in high-risk patients, who represent an unmet medical need.

Clinical trial information: NCT02203643